Consumer Products
Medical
Therapy
Marker Therapeutics
$5.849876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$5.84
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.04 (0.69%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell MRKR and other stocks, options, ETFs, and crypto commission-free!
About
Marker Therapeutics, Inc. Common Stock, also called Marker Therapeutics, is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Read More The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Employees
11
Headquarters
Houston, Texas
Founded
1991
Market Cap
265.63M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
368.69K
High Today
$5.96
Low Today
$5.76
Open Price
$5.80
Volume
121.53K
52 Week High
$13.55
52 Week Low
$3.90
Collections
Consumer Products
Medical
Therapy
Retail
Health
US
North America
News
Yahoo FinanceMay 7
Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
HOUSTON, May 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will be presenting at the 2019 Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, 2019. Marker Therapeutics, Inc. (PRNewsfoto/Marker Therap...
Price Paid on Robinhood
11% Lower
Right Now
52 Week Low
$3.90
Average Price Paid
$6.59
52 Week High
$13.55
Earnings
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, After Hours